Paratek Pharmaceuticals — Investor Day (October 2018)
31 slides from Paratek Pharmaceuticals's investor day presentation, Oct 23, 2018

Slide 1: Investor Day, Lotte Hotel, NYC, October 23, 2018
Investor Day Lotte Hotel, NYC October 23, 2018 Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories. Exhibit 99.1

Slide 2: 2018 Investor Day Agenda
Paratek Pharmaceuticals 2018 Investor Day Agenda Welcoming Comments Michael F. Bigham, Chief Executive Officer and Chairman of the Board Unmet Need & Why NUZYRATM Matters Evan Loh, M.D., President, Chief Operating Officer & Chief Medical Officer NUZYRA Commercial Strategy: 2019 and Beyond Adam Woodr

Slide 3: Welcoming Comments
Welcoming Comments Michael F. Bigham, Chief Executive Officer & Chairman of the Board Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Slide 4: Third-party industry and market information included herein has been obtained from sources believed to
Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The info

Slide 5: Paratek Pipeline
Paratek Pipeline Compelling Life-cycle Opportunities Research Preclinical Phase 1 Phase 2 Phase 3 Pre-Registration NDA Filing NDA Approved Commercial Rights SEYSARATM (sarecycline) (U.S.) (ex-U.S.) (Global*) uUTI (IV & Oral) – QIDP ABSSSI (IV & Oral) – QIDP + SPA CABP (IV & Oral) – QIDP + SPA Inflam

Slide 6: Strong Track Record Delivering on Milestones
Strong Track Record Delivering on Milestones Omadacycline Events Timing Results ABSSSI Phase 3 data: IV and oral Q2 2016 Positive Phase 3 data UTI Phase 1b data: PK/PD Q4 2016 Proof-of-principle CABP Phase 3 data: IV and oral Q2 2017 Positive Phase 3 data ABSSSI Phase 3 data: Oral-only Q3 2017 Posit

Slide 7: Well-Positioned for Future Growth
Well-Positioned for Future Growth Focused on Execution + New Value Creation Near-term Focus New Sources of Value Launch of NUZYRA Prudent Operating Expense Management Non-Dilutive Sources of Capital Life-cycle Opportunities for NUZYRA Bio-Defense Product / Pipeline Expansion

Slide 8: Strong Balance Sheet
Strong Balance Sheet Key Metrics (unaudited) 6/30/18 balance Total Cash, Cash Equivalents, and Marketable Securities $321.1 million Gross Long-term Debt Obligation $218.5 million Basic Shares Outstanding 31,443,149 Stock Options, Restricted Stock Units, and Warrants Outstanding 5,760,108 Funding Pro

Slide 9: Unmet Need & Why NUZYRA Matters
Unmet Need & Why NUZYRA Matters Evan Loh, M.D., President, Chief Operating Officer, Chief Medical Officer Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Slide 10: The Growing Antimicrobial Resistance (AMR) Crisis
The Growing Antimicrobial Resistance (AMR) Crisis Is Here Today, Life-Threatening and Costly More Deaths from AMR than Cancer in 2050

Slide 11: NUZYRA Broad Label Approved on October 2, 2018
NUZYRA…Broad Label Approved on October 2, 2018 Community-acquired bacterial pneumonia (CABP) in adults Acute bacterial skin and skin structure infections (ABSSSI) in adults First Once-daily IV and Oral Antibiotic to be FDA Approved to Treat Both CABP and ABSSSI in Nearly 20 Years

Slide 12: Significant Unmet Need in CABP
Significant Unmet Need in CABP Important Demography: Together with influenza, CABP is currently the eighth leading cause of death in the U.S.3 All cause 30-day mortality in hospitalized patients exceeds 10%4-6 Hospitalization Rates in CABP are increased in older populations and in populations with c

Slide 13: NUZYRA Opportunities Beyond Current CABP Treatment Options
NUZYRA Opportunities Beyond Current CABP Treatment Options: Addressing Limited Formulations with Safety Concerns 1. McLaughlin et al. Infection 2015; 43:671–680. 2. Jain et al. N Engl J Med 2015; 373:415-27. 3. Xu J, et al. National Center for Health Statistics, National Vital Statistics System. 201

Slide 14: Scarcity of Effective & Safe Broad Spectrum IV + Oral Antibiotics
Scarcity of Effective & Safe Broad Spectrum IV + Oral Antibiotics NUZYRA: First Once-daily CABP Indication Approved in Nearly 20 Years 1990’s 2010 2016 2018 2000 ZIGAN Oral TROVAN IV/Oral KETEK Oral TEQUIN IV/Oral LEVAQUIN IV/Oral AVELOX IV/Oral SOLITHERA IV/Oral 2016 Withdrawn from the market due t

Slide 15: Significant Unmet Need in Skin Infections
Significant Unmet Need in Skin Infections Important Demography: Incidence of skin infections requiring hospitalization has substantially increased since the 2000’s1,3 ~ 870,000 admissions, 6.3M office visits, and 3.4M emergency department visits annually5 Underlying co-morbidities including diabetes

Slide 16: NUZYRA Opportunities Beyond Today's Skin Treatment Options
NUZYRA Opportunities Beyond Today’s Skin Treatment Options: Addressing Limited Formulations with Safety Concerns 1.Kaye KS, et al. 2015. PLoS One, 10(11): e0143276 2. Ray et al. BMC Infectious Diseases 2013; 13:252. 3. Esposito et al. Curr Opin Infect Dis 2016, 29:109–115. 4. Pulido-Cejudo A, et al.

Slide 17: NUZYRA: A Modernized Tetracycline
NUZYRA: A Modernized Tetracycline Restoring Tetracycline Efficacy with Convenience Attributes 9-Position Modification: Overcomes Ribosomal Protection 7-Position Modification: Overcomes Efflux Pump T1/2 = 16 Hours Clinical and in-vitro activity against select: Gram-positives, Gram-negatives, Atypical

Slide 18: NUZYRA: Clinically Meaningful Attributes Drive Trial to Adoption
NUZYRA: A Modernized Tetracycline Clinically Meaningful Attributes Drive Trial to Adoption Once-daily IV & Oral High & durable clinical efficacy No dosage modifications or monitoring in hepatic or renal impairment No QTc prolongation Low potential for DDIs No cases of C. diff reported in completed c

Slide 19: Commercial Strategy: 2019 and Beyond
Commercial Strategy: 2019 and Beyond Adam Woodrow, Chief Commercial Officer Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Slide 20: NUZYRA: U.S. Timeline
MSDs Hired/ Deployed NDA Submitted NDA Planned Payer Reimbursement and Trade Discussions Finalize Pricing Scientific Exchange Account Teams Hired Publications/News Flow Continues KPI Dashboard Budget Impact Model and Health Economic Analysis and Publications Sales Teams Hired and Trained Regulatory

Slide 21: NUZYRA: U.S. Timeline, Launch February 2019
MSDs Hired/ Deployed NDA Submitted NDA Accepted Payer Reimbursement and Trade Discussions Finalize Pricing Scientific Exchange Account Teams Hired Publications/News Flow Continues KPI Dashboard Budget Impact Model and Health Economic Analysis and Publications Sales Teams Hired and Trained Regulatory

Slide 22: Success Begins in the Hospital with Specialists
Success Begins in the Hospital with Specialists “Go-Home” Strategy to Minimize Hospital Stay IDs ER HCPs Hospitalists Pulmonologists PharmD IDs Allied HCPs Launch and Beyond HOSPITAL Internal Medicine Primary Care Provider NPs, PAs Urgent Care Year 2 and Beyond COMMUNITY

Slide 23: Paving The Path For a Successful Launch
Paving The Path For a Successful Launch Market Access Followed by Commercial Execution for Demand Generation 2018 2019 2020 Oct ‘18 – Jan ‘19 Execution by Select Customer-Facing Team Contract negotiations Pre-orders Qualify key accounts Appointments February ‘19 - Forward Execution by Sales Force &

Slide 24: Field Force Has Two Simultaneous Objectives
Influencers: IDs PharmD IDs Pharmacy Directors Microbiologists = Field Force Has Two Simultaneous Objectives Institutional Access + Demand Generation Adoption Formulary/Protocols Specialty Access & Buying + Institutional Access Prescribers: IDs ER Hospitalists Pulmonologists Trial & Usage Demand Gen

Slide 25: Focused Launch Targeting Early Adopters
Focused Launch Targeting Early Adopters Expansion to ~80 Representatives by Year End 2019 Physician Segments Guideline and protocol driven Wait for Early Adopters to trial and use Convenient features with IV to oral transition Focused on broad spectrum and efficacy Launch in February 2019 with 40 Sa

Slide 26: There are Unmet Needs that NUZYRA Will Address
More Oral Options New Therapies to Overcome Drug Resistance Greater Safety Alternative to Quinolones There are Unmet Needs that NUZYRA Will Address Reduce Hospital Length of Stay Reduce Nursing Time Lack of Different Class Options Reduce Usage of Multi-Drug Combinations NUZYRA Attributes Provide A M

Slide 27: NUZYRA: As First-line Therapy
NUZYRA: As First-line Therapy Targeted Patient Profiles CABP ABSSSI Alternative to fluoroquinolone + β-lactam allergic Prior C. difficile infection Suspected polymicrobial infection + β-lactam / sulfa allergic Renal insufficiency + SSRI

Slide 28: Ensure Seamless Transition from Hospital to Home
Ensure Seamless Transition from Hospital to Home Continuity of Care Providing Access to Oral NUZYRA Continuity of Care Prevent gap in care Sample / Bridge Program (as needed) Reimbursement Support Services Affordability Program 3 Distribution Network IV Formulation National & Regional Distributors O

Slide 29: Early Indicators to Track Performance
Early Indicators to Track Performance 1 Covered Lives Institutional Access 3 months Post-Launch 33% of covered lives under contract 12 months Post-Launch 66% of covered lives under contract 12 months Post-Launch 70% of 800 targeted institutions

Slide 30: History Can Repeat Itself
History Can Repeat Itself… Today: Slower starts…But with the Right Attributes, a Strong Finish Recent AB Launches: antibiotics launched since 2010 that have at least 36 months of data - Avycaz, Dalvance, Orbactiv, Sivextro, Teflaro, & Zerbaxa (does not include Dificid or new formulations/line extens

Slide 31: NUZYRA Coming Soon…February 2019
NUZYRA Coming Soon…February 2019 1
Source: SEC EDGAR · 8-K filed Oct 23, 2018
More decks from Paratek Pharmaceuticals Inc
FY2020 Earnings Presentation31 slides · Feb 24, 2021
FY2019 Earnings Presentation23 slides · Feb 25, 2020
FY2018 Earnings Presentation24 slides · Feb 27, 2019
Investor Presentation (January 2019)45 slides · Jan 4, 2019
Q3 2018 Earnings Presentation20 slides · Nov 6, 2018
Investor Presentation (January 2018)39 slides · Jan 5, 2018